CryoCell International Financials
CCEL Stock | USD 8.35 0.05 0.60% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.49 | 0.52 |
|
|
Investors should never underestimate CryoCell International's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CryoCell International's cash flow, debt, and profitability to make informed and accurate decisions about investing in CryoCell International.
Net Income |
|
CryoCell | Select Account or Indicator |
Understanding current and past CryoCell International Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CryoCell International's financial statements are interrelated, with each one affecting the others. For example, an increase in CryoCell International's assets may result in an increase in income on the income statement.
CryoCell International Stock Summary
CryoCell International competes with National HealthCare, InnovAge Holding, Pennant, Encompass Health, and Airsculpt Technologies. Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida. Cryo-Cell Intl operates under Medical Care Facilities classification in the United States and is traded on AMEX Exchange. It employs 83 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NYSE MKT Exchange |
ISIN | US2288951088 |
CUSIP | 228895108 |
Location | Florida; U.S.A |
Business Address | 700 Brooker Creek |
Sector | Health Care Providers & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.cryo-cell.com |
Phone | 813 749 2100 |
Currency | USD - US Dollar |
CryoCell International Key Financial Ratios
Return On Equity | 1.29 | ||||
Profit Margin | (0.28) % | ||||
Operating Margin | 0.17 % | ||||
Price To Sales | 2.10 X | ||||
Revenue | 31.34 M |
CryoCell International Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 46.2M | 60.7M | 64.9M | 61.2M | 70.4M | 73.9M | |
Other Current Liab | 1.9M | 8.0M | 5.2M | 4.9M | 5.7M | 6.0M | |
Net Debt | (4.1M) | (5.4M) | 9.9M | 10.5M | 9.4M | 9.0M | |
Retained Earnings | (18.8M) | (16.7M) | (21.6M) | (31.2M) | (28.0M) | (29.4M) | |
Accounts Payable | 957.4K | 1.5M | 1.6M | 3.2M | 3.7M | 3.8M | |
Cash | 10.4M | 8.3M | 1.7M | 406.1K | 467.0K | 443.6K | |
Net Receivables | 6.3M | 5.3M | 6.0M | 6.6M | 7.6M | 7.9M | |
Total Liab | 48.9M | 56.5M | 66.4M | 72.3M | 83.1M | 87.2M | |
Total Current Assets | 18.6M | 15.8M | 9.6M | 9.5M | 10.9M | 10.5M | |
Intangible Assets | 1.5M | 16.2M | 15.2M | 989.1K | 1.1M | 2.0M | |
Other Current Assets | 856.3K | 1.3M | 993.4K | 1.1M | 1.3M | 871.7K | |
Short Term Debt | 3.4M | 2.2M | 2.7M | 1.6M | 1.9M | 1.6M | |
Common Stock | 136.3K | 146.7K | 148.5K | 148.5K | 170.8K | 134.7K | |
Other Liab | 28.6M | 29.6M | 34.8M | 38.0M | 43.7M | 45.9M | |
Other Assets | 22.2M | 21.9M | 22.3M | 23.7M | 27.2M | 28.6M | |
Long Term Debt | 5.9M | 2.8M | 8.6M | 8.4M | 9.7M | 5.2M | |
Net Tangible Assets | (10.1M) | (2.7M) | (14.0M) | (18.6M) | (16.8M) | (17.6M) | |
Inventory | 927.3K | 921.2K | 851.2K | 768.9K | 692.0K | 657.4K |
CryoCell International Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Revenue | 31.1M | 28.9M | 30.3M | 31.3M | 36.0M | 18.4M | |
Gross Profit | 21.5M | 19.9M | 21.5M | 22.9M | 26.3M | 27.7M | |
Operating Income | 7.7M | 4.0M | 4.0M | (12.3M) | (14.1M) | (13.4M) | |
Ebit | 6.6M | 4.0M | 4.8M | (12.1M) | (13.9M) | (13.2M) | |
Ebitda | 7.2M | 5.3M | 6.7M | (10.4M) | (12.0M) | (11.4M) | |
Cost Of Revenue | 9.7M | 9.0M | 8.8M | 8.4M | 9.7M | 5.6M | |
Income Before Tax | 5.0M | 2.6M | 3.3M | (13.4M) | (15.4M) | (14.6M) | |
Net Income | 3.6M | 2.1M | 2.8M | (9.5M) | (10.9M) | (10.4M) | |
Income Tax Expense | 1.4M | 527.7K | 547.5K | (3.8M) | (4.4M) | (4.2M) | |
Research Development | 23.9K | 49.9K | 384.8K | 1.2M | 1.3M | 1.4M | |
Interest Expense | 1.5M | 1.4M | 1.5M | 1.2M | 1.4M | 1.2M | |
Tax Provision | 1.4M | 527.7K | 547.5K | (3.8M) | (3.5M) | (3.3M) | |
Net Interest Income | (1.5M) | (1.4M) | (1.5M) | (1.2M) | (1.1M) | (1.2M) |
CryoCell International Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 3.8M | (2.1M) | (6.6M) | (1.3M) | (1.2M) | (1.1M) | |
Free Cash Flow | 8.0M | 974.9K | (8.6M) | 1.3M | 1.5M | 1.2M | |
Depreciation | 636.0K | 1.3M | 1.8M | 1.7M | 2.0M | 2.1M | |
Other Non Cash Items | 1.1M | 1.0M | 1.0M | 16.7M | 19.2M | 20.1M | |
Capital Expenditures | 450.0K | 7.0M | 17.2M | 7.6M | 8.8M | 9.2M | |
Net Income | 3.6M | 2.1M | 2.8M | (9.5M) | (10.9M) | (10.4M) | |
End Period Cash Flow | 10.4M | 8.3M | 1.7M | 406.1K | 467.0K | 443.6K | |
Change To Inventory | 454.9K | 210.3K | 490.0K | 360.4K | 324.4K | 264.9K | |
Investments | 457.4K | (7.0M) | (15.3M) | (8.1M) | (7.3M) | (7.0M) | |
Change To Netincome | 1.2M | 365.2K | (397.4K) | (274.3K) | (246.9K) | (234.6K) | |
Net Borrowings | 5.5M | (4.1M) | (3.1M) | 9.3M | 8.4M | 8.8M |
CryoCell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CryoCell International's current stock value. Our valuation model uses many indicators to compare CryoCell International value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CryoCell International competition to find correlations between indicators driving CryoCell International's intrinsic value. More Info.CryoCell International is number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, CryoCell International's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value CryoCell International by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CryoCell International Systematic Risk
CryoCell International's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CryoCell International volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on CryoCell International correlated with the market. If Beta is less than 0 CryoCell International generally moves in the opposite direction as compared to the market. If CryoCell International Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CryoCell International is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CryoCell International is generally in the same direction as the market. If Beta > 1 CryoCell International moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in CryoCell International Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CryoCell International's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of CryoCell International growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
CryoCell International November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CryoCell International help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CryoCell International. We use our internally-developed statistical techniques to arrive at the intrinsic value of CryoCell International based on widely used predictive technical indicators. In general, we focus on analyzing CryoCell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CryoCell International's daily price indicators and compare them against related drivers.
Downside Deviation | 2.75 | |||
Information Ratio | 0.057 | |||
Maximum Drawdown | 30.49 | |||
Value At Risk | (4.42) | |||
Potential Upside | 7.14 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Earnings Share (1.07) | Revenue Per Share 3.89 | Quarterly Revenue Growth 0.025 | Return On Assets (0) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.